



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## 4-Hydroxyisoleucine

<b>Cat. No.:</b>	HY-N6858		
<b>CAS No.:</b>	781658-23-9		
<b>Molecular Formula:</b>	C <sub>6</sub> H <sub>13</sub> NO <sub>3</sub>		
<b>Molecular Weight:</b>	147		
<b>Target:</b>	Others		
<b>Pathway:</b>	Others		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : 100 mg/mL (680.27 mM; Need ultrasonic)  
 DMSO : < 1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble or slightly soluble)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	6.8027 mL	34.0136 mL	68.0272 mL
	5 mM	1.3605 mL	6.8027 mL	13.6054 mL
	10 mM	0.6803 mL	3.4014 mL	6.8027 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

1. Add each solvent one by one: PBS  
 Solubility: 100 mg/mL (680.27 mM); Clear solution; Need ultrasonic

### BIOLOGICAL ACTIVITY

#### Description

4-Hydroxyisoleucine is an orally active amino acid that can be isolated from fenugreek seeds. 4-Hydroxyisoleucine displays insulinotropic and antidiabetic properties<sup>[1]</sup>.

#### In Vitro

4-Hydroxyisoleucine (20 μM, 6 h) decreases the level of iRhom2, TACE, TNF-α and MCP-1 in RAW264.7 macrophages and 3 T3-L1 adipocytes with LPS (HY-D1056) induction<sup>[2]</sup>.  
 4-Hydroxyisoleucine (20 μM, 6 h) increases the product of M1 macrophage IL-6 and decreases the product of M2 macrophage IL-10 in the co-culture system with LPS (HY-D1056) stimulation<sup>[2]</sup>.  
 4-Hydroxyisoleucine (0-25 μM, 16 h) increases glucose uptake and surface GLUT4myc level in L6-GLUT4myc myotubes in a concentration-dependent manner<sup>[3]</sup>.  
 4-Hydroxyisoleucine (0-25 μM, 16 h) stimulates GLUT4myc translocation via PI-3-K/AKT-dependent mechanisms in L6-GLUT4myc myotubes<sup>[3]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### Cell Viability Assay<sup>[2]</sup>

Cell Line:	RAW264.7 macrophages and 3 T3-L1 adipocytes
Concentration:	0-20 $\mu$ M
Incubation Time:	6 h
Result:	Didn't affect the cell viability.

#### Cell Migration Assay <sup>[2]</sup>

Cell Line:	RAW264.7 macrophages and 3 T3-L1 adipocytes
Concentration:	20 $\mu$ M
Incubation Time:	24 h
Result:	Inhibited the migration of RAW264.7 macrophages in 3 T3-L1 adipocytes.

#### Western Blot Analysis<sup>[3]</sup>

Cell Line:	L6-GLUT4myc
Concentration:	25 $\mu$ M
Incubation Time:	16 h
Result:	Increased the AKT (Ser-473) phosphorylation. Didn't effect mRNA levels of IRS-1, AKT, GSK3b, or GLUT4 in L6-GLUT4myc myotubes.

#### In Vivo

4-Hydroxyisoleucine (50 mg/kg, p.o., daily, 8 weeks) inhibits the increase in serum glucose in the fructose-fed rat model of metabolic syndrome<sup>[1]</sup>.

4-Hydroxyisoleucine (200 mg/kg, p.o., 8 weeks) improves dyslipidemia and reduces lipid ectopic accumulation in C57BL/6 mice<sup>[4]</sup>.

4-Hydroxyisoleucine (200 mg/kg, p.o., 8 weeks) decreases the expression of proinflammatory cytokine (IL-6, PAI-1, IL-1 $\beta$ , NF- $\kappa$ B, TNF- $\alpha$ , and MCP-1) and the proportion of proinflammatory M1 macrophages in C57BL/6 mice<sup>[4]</sup>.

4-Hydroxyisoleucine (50 mg/kg, i.g., daily, 14 days) restores high levels of lipids (cholesterol, HDL, LDL and triglycerides) and uric acid in type 1 diabetic rat to that of nondiabetic controls level<sup>[5]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Fructose-fed rat <sup>[1]</sup>
Dosage:	50 mg/kg
Administration:	Oral gavage (p.o.), daily, 8 weeks
Result:	Decreased the levels of glucose and ALT. Reduced 80% of fructose-induced AST release to 151 $\pm$ 45 U/mL.

Animal Model:	Type 2 diabetic rat <sup>[1]</sup>
Dosage:	50 mg/kg
Administration:	i.g., daily, 14 days

Result:	Restored the level of HDL-cholesterol to levels comparable to controls.
Animal Model:	Male C57BL/6 mice <sup>[4]</sup>
Dosage:	50-200 mg/kg
Administration:	Oral gavage (p.o.), 8 weeks
Result:	Decreases the body weights of mice in a dose-dependent manner. Decreased blood glucose levels and fasting plasma insulin content in mice. Decreased the expression of TLR4, inhibited the phosphorylation of JNK, and increased the production of I $\kappa$ B- $\alpha$ .
Animal Model:	Type 1 diabetic rat <sup>[5]</sup>
Dosage:	50 mg/kg
Administration:	i.g., daily, 14 days
Result:	Improved appearance and heavy ocular vascularization. Reduced the blood glucose from 500 mg/dl to 330 mg/dl. Decreased the levels of lipid markers (TG, LDL and HDL) and uric acid. Didn't increase the level of inculin compared with untreated diabetic controls.

## REFERENCES

- [1]. Haeri MR, et al. The effect of fenugreek 4-hydroxyisoleucine on liver function biomarkers and glucose in diabetic and fructose-fed rats. *Phytother Res.* 2009 Jan;23(1):61-4.
- [2]. Zhou C, et al. 4-Hydroxyisoleucine relieves inflammation through iRhom2-dependent pathway in co-cultured macrophages and adipocytes with LPS stimulation. *BMC Complement Med Ther.* 2020 Dec 9;20(1):373.
- [3]. Jaiswal N, et al. 4-Hydroxyisoleucine stimulates glucose uptake by increasing surface GLUT4 level in skeletal muscle cells via phosphatidylinositol-3-kinase-dependent pathway. *Eur J Nutr.* 2012 Oct;51(7):893-8.
- [4]. Yang J, et al. 4-Hydroxyisoleucine Alleviates Macrophage-Related Chronic Inflammation and Metabolic Syndrome in Mice Fed a High-Fat Diet. *Front Pharmacol.* 2021 Jan 21;11:606514.
- [5]. Haeri MR, et al. Non-insulin dependent anti-diabetic activity of (2S, 3R, 4S) 4-hydroxyisoleucine of fenugreek (*Trigonella foenum graecum*) in streptozotocin-induced type I diabetic rats. *Phytomedicine.* 2012 May 15;19(7):571-4.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA